Bliss GVS Pharma Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Efficient capital deployment (ROCE 16.9%)
- Virtually debt-free
Concerns
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
BLISSGVS · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 34.97% | 34.97% | 34.90% | 34.82% | 35.10% | 35.29% |
| FII | 15.35% | 14.74% | 13.24% | 12.13% | 13.51% | 13.18% |
| DII | 6.60% | 6.59% | 6.58% | 6.56% | 6.55% | 6.55% |
| Public | 43.08% | 43.71% | 45.27% | 46.49% | 44.84% | 44.98% |
Corporate Events
To consider and approve the financial results for the period ended September 30, 2026 and other business matters
To consider Fund Raising and other business matters
Dividend - Re 1 Per Share
To consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters
Interim Dividend - Re 0.50 Per Share
Annual General Meeting/Dividend - Rs 0.50 Per Share
Annual General Meeting/Dividend - Rs 0.50 Per Share
Annual General Meeting/Dividend - Re 0.50 Per Share
Latest News
All newsBliss GVS Pharma hits 52-week high on WHO approval and strong earnings
*Bliss GVS Pharma hits 52-week high on WHO approval and strong earnings* — Shares of Bliss GVS Pharma surged to a 52-week high of **₹447** following WHO's approval of its manufacturing facility. The stock rallied on the back of strong quarterly earnings and positive sentiment from a recent acquisition. Investors are optimistic about expanded global market access and future revenue growth. 📊 *STOCKS:* BLISSGVS | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Pharma
Anupam Rasayan announces equity stake in Bliss GVS Pharma
*Anupam Rasayan announces equity stake in Bliss GVS Pharma* — The company has acquired a strategic equity interest in Bliss GVS Pharma Limited, marking a move into the pharma space. The size and value of the stake were not disclosed. This corporate action may signal diversification or synergy plans between the two firms. 📊 *STOCKS:* ANUPAMR, BLISSGVS | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #StakeAcquisition
Bliss GVS Pharma publishes statutory notice in newspaper
*Bliss GVS Pharma publishes statutory notice in newspaper.* This is a routine corporate filing requirement, typically related to board meetings or shareholder communications. No **financial figures** or **strategic developments** are disclosed in the headline. Such notices are standard compliance actions under listing regulations. 📊 *STOCKS:* $BLISSGVS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #CorporateFiling
Bliss GVS Pharma announces re-lodgement window for physical shares
*Bliss GVS Pharma announces special window for re-lodgement of transfer requests for physical shares.* This facilitates shareholders who faced issues in earlier submissions. The move supports smoother share transfer operations and enhances investor service. Details are available in the NSE filing. 📊 *STOCKS:* BGL | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ShareTransfer
Bliss GVS Pharma publishes postal ballot notice in newspaper
*Bliss GVS Pharma publishes postal ballot notice in newspaper.* This is part of a mandatory corporate disclosure process for shareholder voting. The filing indicates procedural compliance with SEBI regulations. No financial or operational impact is expected from this routine notice. 📊 *STOCKS:* $BGL | 🏢 *SECTOR:* Pharma | #LOWIMPACT #CorporateFiling
Bliss GVS Pharma shares unaffected; updates KMP contact details
*Bliss GVS Pharma updates contact details of Key Management Personnel for reporting material events.* This is a routine compliance disclosure with no immediate financial impact. **No trading-sensitive information** or strategic changes disclosed. Investors advised to monitor for future announcements. 📊 *STOCKS:* BGL | 🏢 *SECTOR:* Pharma | #LOWIMPACT #KMP
Bliss GVS Pharma announces 41st AGM via newspaper notice
*Bliss GVS Pharma announces 41st AGM via newspaper publication.* The date, time, and agenda of the meeting will be disclosed as per regulatory norms. Shareholders are advised to watch for further announcements. Dividend details, if any, will be revealed during the meet. 📊 *STOCKS:* BLISSGVS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #AGM
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹218 Cr 10.7% | ₹244 Cr 17.9% | ₹207 Cr 4.5% | ₹198 Cr 5.7% | ₹210 Cr 3.7% | ₹218 Cr 18.5% | ₹184 Cr 7.1% | ₹198 Cr |
| Op. Profit | ₹35 Cr 18.6% | ₹43 Cr 4.9% | ₹41 Cr 95.2% | ₹21 Cr 30.0% | ₹30 Cr 26.8% | ₹41 Cr 20.6% | ₹34 Cr 21.4% | ₹28 Cr |
| OPM | 16.0% 11.1% | 18.0% 10.0% | 20.0% 81.8% | 11.0% 21.4% | 14.0% 26.3% | 19.0% 0.0% | 19.0% 35.7% | 14.0% |
| Net Profit | ₹25 Cr 13.8% | ₹29 Cr 34.1% | ₹44 Cr 158.8% | ₹17 Cr 34.6% | ₹26 Cr 0.0% | ₹26 Cr 18.2% | ₹22 Cr 540.0% | ₹-5 Cr |
| EPS (₹) | 2.2 14.7% | 2.58 36.8% | 4.08 177.6% | 1.47 35.0% | 2.26 2.2% | 2.31 17.3% | 1.97 326.4% | -0.87 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹927 Cr 14.4% | ₹810 Cr 5.2% | ₹770 Cr 2.4% | ₹752 Cr 0.7% | ₹747 Cr 29.5% | ₹577 Cr 16.3% | ₹689 Cr 23.4% | ₹899 Cr 10.3% | ₹815 Cr 2.1% | ₹798 Cr |
| Expenses | ₹760 Cr 11.3% | ₹683 Cr 10.2% | ₹620 Cr 2.2% | ₹634 Cr 0.8% | ₹629 Cr 33.5% | ₹471 Cr 16.8% | ₹566 Cr 23.4% | ₹739 Cr 19.6% | ₹618 Cr 3.7% | ₹596 Cr |
| Op. Profit | ₹168 Cr 32.3% | ₹127 Cr 15.9% | ₹151 Cr 29.1% | ₹117 Cr 0.8% | ₹118 Cr 10.3% | ₹107 Cr 13.0% | ₹123 Cr 23.1% | ₹160 Cr 18.8% | ₹197 Cr 3.0% | ₹203 Cr |
| OPM | 18.0% 12.5% | 16.0% 20.0% | 20.0% 25.0% | 16.0% 0.0% | 16.0% 11.1% | 18.0% 0.0% | 18.0% 0.0% | 18.0% 25.0% | 24.0% 4.0% | 25.0% |
| Other Income | ₹67 Cr 86.1% | ₹36 Cr | ₹0 Cr 100.0% | ₹18 Cr 142.9% | ₹-42 Cr 310.0% | ₹20 Cr 23.1% | ₹26 Cr 25.7% | ₹35 Cr 537.5% | ₹-8 Cr 166.7% | ₹12 Cr |
| Interest | ₹12 Cr 50.0% | ₹8 Cr 14.3% | ₹7 Cr 30.0% | ₹10 Cr 100.0% | ₹5 Cr 16.7% | ₹6 Cr 25.0% | ₹8 Cr 100.0% | ₹4 Cr 82.6% | ₹23 Cr 15.0% | ₹20 Cr |
| Depreciation | ₹33 Cr 13.8% | ₹29 Cr 11.5% | ₹26 Cr 36.8% | ₹19 Cr 11.8% | ₹17 Cr 0.0% | ₹17 Cr 30.8% | ₹13 Cr 44.4% | ₹9 Cr 57.1% | ₹21 Cr 5.0% | ₹20 Cr |
| PBT | ₹190 Cr 50.8% | ₹126 Cr 7.7% | ₹117 Cr 10.4% | ₹106 Cr 96.3% | ₹54 Cr 48.1% | ₹104 Cr 19.4% | ₹129 Cr 29.1% | ₹182 Cr 25.5% | ₹145 Cr 17.1% | ₹175 Cr |
| Tax % | 29.0% 3.6% | 28.0% 6.7% | 30.0% 7.1% | 28.0% 50.9% | 57.0% 96.6% | 29.0% 11.5% | 26.0% 13.3% | 30.0% 23.1% | 39.0% 8.3% | 36.0% |
| Net Profit | ₹135 Cr 50.0% | ₹90 Cr 9.8% | ₹82 Cr 6.5% | ₹77 Cr 234.8% | ₹23 Cr 68.9% | ₹74 Cr 22.1% | ₹95 Cr 25.2% | ₹127 Cr 42.7% | ₹89 Cr 21.2% | ₹113 Cr |
| EPS (₹) | 12.21 52.6% | 8 11.0% | 7.21 6.0% | 6.8 369.0% | 1.45 78.2% | 6.64 29.6% | 9.43 21.4% | 11.99 110.4% | 5.7 28.3% | 7.95 |
| Div Payout | 4.0% 33.3% | 6.0% 14.3% | 7.0% 0.0% | 7.0% 79.4% | 34.0% 325.0% | 8.0% 60.0% | 5.0% 37.5% | 8.0% 55.6% | 18.0% 125.0% | 8.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Liabilities | ||||||||||
| Equity Capital | ₹11 Cr 0.0% | ₹11 Cr 10.0% | ₹10 Cr 0.0% | ₹10 Cr 0.0% | ₹10 Cr 0.0% | ₹10 Cr 0.0% | ₹10 Cr 0.0% | ₹10 Cr 0.0% | ₹10 Cr 0.0% | ₹10 Cr |
| Reserves | ₹1.1K Cr 7.9% | ₹1.0K Cr 8.7% | ₹957 Cr 9.6% | ₹873 Cr 8.0% | ₹808 Cr 1.3% | ₹798 Cr 10.1% | ₹725 Cr 14.0% | ₹636 Cr 20.9% | ₹526 Cr 10.5% | ₹476 Cr |
| Borrowings | ₹52 Cr 40.9% | ₹88 Cr 12.0% | ₹100 Cr 2.0% | ₹102 Cr 6.4% | ₹109 Cr 10.7% | ₹122 Cr 3.2% | ₹126 Cr 23.5% | ₹102 Cr 13.6% | ₹118 Cr 47.6% | ₹225 Cr |
| Other Liabilities | ₹215 Cr 31.9% | ₹163 Cr 12.4% | ₹145 Cr 15.2% | ₹171 Cr 5.5% | ₹181 Cr 23.1% | ₹147 Cr 12.5% | ₹168 Cr 7.0% | ₹157 Cr 23.8% | ₹206 Cr 33.8% | ₹311 Cr |
| Total Liabilities | ₹1.4K Cr 7.6% | ₹1.3K Cr 7.3% | ₹1.2K Cr 4.8% | ₹1.2K Cr 4.3% | ₹1.1K Cr 3.0% | ₹1.1K Cr 4.6% | ₹1.0K Cr 13.8% | ₹905 Cr 5.2% | ₹860 Cr 15.9% | ₹1.0K Cr |
Assets | ||||||||||
| Fixed Assets | ₹392 Cr 3.4% | ₹406 Cr 9.7% | ₹370 Cr 2.4% | ₹379 Cr 34.9% | ₹281 Cr 20.1% | ₹234 Cr 3.3% | ₹242 Cr 65.8% | ₹146 Cr 2.1% | ₹143 Cr 53.1% | ₹305 Cr |
| CWIP | ₹39 Cr 85.7% | ₹21 Cr 162.5% | ₹8 Cr 166.7% | ₹3 Cr 86.4% | ₹22 Cr 1000.0% | ₹2 Cr | ₹0 Cr 100.0% | ₹47 Cr | ₹0 Cr 100.0% | ₹4 Cr |
| Investments | ₹10 Cr 150.0% | ₹4 Cr 0.0% | ₹4 Cr 50.0% | ₹8 Cr 300.0% | ₹2 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other Assets | ₹959 Cr 10.1% | ₹871 Cr 4.9% | ₹830 Cr 8.1% | ₹768 Cr 4.4% | ₹803 Cr 4.4% | ₹840 Cr 6.6% | ₹788 Cr 10.7% | ₹712 Cr 0.7% | ₹717 Cr 0.4% | ₹714 Cr |
| Total Assets | ₹1.4K Cr 7.6% | ₹1.3K Cr 7.3% | ₹1.2K Cr 4.8% | ₹1.2K Cr 4.3% | ₹1.1K Cr 3.0% | ₹1.1K Cr 4.6% | ₹1.0K Cr 13.8% | ₹905 Cr 5.2% | ₹860 Cr 15.9% | ₹1.0K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹106 Cr 2.9% | ₹103 Cr 202.9% | ₹34 Cr 74.8% | ₹135 Cr 110.9% | ₹64 Cr 36.2% | ₹47 Cr 17.5% | ₹40 Cr 122.2% | ₹18 Cr 93.8% | ₹289 Cr 155.8% | ₹113 Cr |
| Investing CF | ₹-75 Cr 9.6% | ₹-83 Cr 1283.3% | ₹-6 Cr 94.2% | ₹-103 Cr 128.9% | ₹-45 Cr 12.5% | ₹-40 Cr 49.4% | ₹-79 Cr 264.6% | ₹48 Cr 119.3% | ₹-249 Cr 398.0% | ₹-50 Cr |
| Financing CF | ₹-30 Cr 42.9% | ₹-21 Cr 16.0% | ₹-25 Cr 4.2% | ₹-24 Cr 14.3% | ₹-21 Cr 250.0% | ₹-6 Cr 135.3% | ₹17 Cr 122.4% | ₹-76 Cr 660.0% | ₹-10 Cr 75.0% | ₹-40 Cr |
| Net Cash Flow | ₹0 Cr 100.0% | ₹-1 Cr 133.3% | ₹3 Cr 66.7% | ₹9 Cr 550.0% | ₹-2 Cr | ₹0 Cr 100.0% | ₹-22 Cr 120.0% | ₹-10 Cr 133.3% | ₹30 Cr 30.4% | ₹23 Cr |
| Free Cash Flow | ₹33 Cr 56.0% | ₹75 Cr 227.1% | ₹-59 Cr 193.7% | ₹63 Cr 14.5% | ₹55 Cr 558.3% | ₹-12 Cr 700.0% | ₹2 Cr 128.6% | ₹-7 Cr 103.8% | ₹186 Cr 84.2% | ₹101 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 198d 3.1% | 192d 2.7% | 187d 2.6% | 192d 34.5% | 293d 1.0% | 290d 55.1% | 187d 39.6% | 134d 15.5% | 116d 42.3% | 201d |
| Inventory Days | 111d 1.8% | 113d 20.2% | 94d 19.0% | 116d 5.5% | 110d 71.9% | 64d 39.1% | 46d 16.4% | 55d 10.0% | 50d 9.1% | 55d |
| Days Payable | 63d 8.6% | 58d 26.6% | 79d 8.1% | 86d 4.9% | 82d 9.3% | 75d 59.6% | 47d 14.5% | 55d 45.0% | 100d 34.6% | 153d |
| Cash Conv. Cycle | 246d 0.4% | 247d 22.3% | 202d 8.6% | 221d 31.2% | 321d 15.1% | 279d 50.0% | 186d 38.8% | 134d 100.0% | 67d 34.3% | 102d |
| Working Capital Days | 198d 4.3% | 207d 7.8% | 192d 7.3% | 179d 32.2% | 264d 13.8% | 232d 50.6% | 154d 14.1% | 135d 1450.0% | -10d 111.9% | 84d |
| ROCE | 12.0% 14.3% | 14.0% 16.7% | 12.0% 14.3% | 14.0% 16.7% | 12.0% 33.3% | 18.0% 30.8% | 26.0% 3.7% | 27.0% 6.9% | 29.0% 6.5% | 31.0% |
Source: Screener.in · Lower days = better efficiency
About Bliss GVS Pharma Limited
Incorporated in 1984, Bliss GVS Pharma Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical formulations in the form of suppositories, pessaries, capsules, tablets, and syrups.
HealthcarePharmaceuticals & Biotechnology